報價延遲最少15分鐘:2025/07/18 07:02 EDT
盤前時段
|
||||
|
2.15 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.16
|
|
|
| 價值評估 |
|
盈利(現時/預測)
110.31/-0.05
|
|
企業價值
5.26M
|
| 資產負債 |
|
每股賬面淨值
1.29
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/18 07:02 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals. |
